본문으로 건너뛰기
← 뒤로

Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome.

1/5 보강
BMJ case reports 📖 저널 OA 40.9% 2021: 14/14 OA 2022: 17/17 OA 2023: 7/7 OA 2024: 2/12 OA 2025: 7/73 OA 2026: 4/71 OA 2021~2026 2025 Vol.18(9)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
neoadjuvant gemcitabine and split-dose cisplatin, leading to a complete pathological response, ypT0N0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
An initial attempt to obtain an insurance approval for pembrolizumab given LS and context of deficient mismatch repair was unsuccessful. She subsequently received neoadjuvant gemcitabine and split-dose cisplatin, leading to a complete pathological response, ypT0N0.

Notardonato L, Wahab A, Reizine N, Tawagi K

📝 환자 설명용 한 줄

Lynch syndrome (LS)-associated upper tract urothelial cancer (UTUC) is an overall rare malignancy comprising only 5%-10% of all urothelial carcinomas.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Notardonato L, Wahab A, et al. (2025). Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome.. BMJ case reports, 18(9). https://doi.org/10.1136/bcr-2025-265380
MLA Notardonato L, et al.. "Peri-operative management considerations for localised upper tract urothelial carcinoma in the setting of Lynch syndrome.." BMJ case reports, vol. 18, no. 9, 2025.
PMID 41033700 ↗

Abstract

Lynch syndrome (LS)-associated upper tract urothelial cancer (UTUC) is an overall rare malignancy comprising only 5%-10% of all urothelial carcinomas. Given its rarity, specific management guidelines for LS-associated UTUC do not exist. The optimal peri-operative management of localised LS-UTUC remains unknown, and with future approvals, immunotherapy may allow for organ preservation. This report describes a case of localised LS-UTUC with prior history of stage I colon cancer. An initial attempt to obtain an insurance approval for pembrolizumab given LS and context of deficient mismatch repair was unsuccessful. She subsequently received neoadjuvant gemcitabine and split-dose cisplatin, leading to a complete pathological response, ypT0N0.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반